FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898055118> ?p ?o ?g. }

• W2898055118 endingPage "604" @default.
• W2898055118 startingPage "596" @default.
• W2898055118 abstract "Dysferlinopathy is a progressive myopathy caused by mutations in the dysferlin (DYSF) gene. Dysferlin protein plays a major role in plasma-membrane resealing. Some patients with DYSF deletion mutations exhibit mild symptoms, suggesting some regions of DYSF can be removed without significantly impacting protein function. Antisense-mediated exon-skipping therapy uses synthetic molecules called antisense oligonucleotides to modulate splicing, allowing exons harboring or near genetic mutations to be removed and the open reading frame corrected. Previous studies have focused on DYSF exon 32 skipping as a potential therapeutic approach, based on the association of a mild phenotype with the in-frame deletion of exon 32. To date, no other DYSF exon-skipping targets have been identified, and the relationship between DYSF exon deletion pattern and protein function remains largely uncharacterized. In this study, we utilized a membrane-wounding assay to evaluate the ability of plasmid constructs carrying mutant DYSF, as well as antisense oligonucleotides, to rescue membrane resealing in patient cells. We report that multi-exon skipping of DYSF exons 26–27 and 28–29 rescues plasma-membrane resealing. Successful translation of these findings into the development of clinical antisense drugs would establish new therapeutic approaches that would be applicable to ∼5%–7% (exons 26–27 skipping) and ∼8% (exons 28–29 skipping) of dysferlinopathy patients worldwide. Dysferlinopathy is a progressive myopathy caused by mutations in the dysferlin (DYSF) gene. Dysferlin protein plays a major role in plasma-membrane resealing. Some patients with DYSF deletion mutations exhibit mild symptoms, suggesting some regions of DYSF can be removed without significantly impacting protein function. Antisense-mediated exon-skipping therapy uses synthetic molecules called antisense oligonucleotides to modulate splicing, allowing exons harboring or near genetic mutations to be removed and the open reading frame corrected. Previous studies have focused on DYSF exon 32 skipping as a potential therapeutic approach, based on the association of a mild phenotype with the in-frame deletion of exon 32. To date, no other DYSF exon-skipping targets have been identified, and the relationship between DYSF exon deletion pattern and protein function remains largely uncharacterized. In this study, we utilized a membrane-wounding assay to evaluate the ability of plasmid constructs carrying mutant DYSF, as well as antisense oligonucleotides, to rescue membrane resealing in patient cells. We report that multi-exon skipping of DYSF exons 26–27 and 28–29 rescues plasma-membrane resealing. Successful translation of these findings into the development of clinical antisense drugs would establish new therapeutic approaches that would be applicable to ∼5%–7% (exons 26–27 skipping) and ∼8% (exons 28–29 skipping) of dysferlinopathy patients worldwide." @default.
• W2898055118 created "2018-10-26" @default.
• W2898055118 creator A5019939682 @default.
• W2898055118 creator A5045237664 @default.
• W2898055118 creator A5078187049 @default.
• W2898055118 creator A5080323628 @default.
• W2898055118 creator A5084705297 @default.
• W2898055118 date "2018-12-01" @default.
• W2898055118 modified "2023-10-16" @default.
• W2898055118 title "Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy" @default.
• W2898055118 cites W1551910894 @default.
• W2898055118 cites W1592698849 @default.
• W2898055118 cites W1799444595 @default.
• W2898055118 cites W1969099911 @default.
• W2898055118 cites W1974248631 @default.
• W2898055118 cites W1980069790 @default.
• W2898055118 cites W1982839027 @default.
• W2898055118 cites W1983351039 @default.
• W2898055118 cites W1991180491 @default.
• W2898055118 cites W1995150314 @default.
• W2898055118 cites W2004552697 @default.
• W2898055118 cites W2011960556 @default.
• W2898055118 cites W2018678459 @default.
• W2898055118 cites W2018810553 @default.
• W2898055118 cites W2021853034 @default.
• W2898055118 cites W2024664316 @default.
• W2898055118 cites W2031223556 @default.
• W2898055118 cites W2039381665 @default.
• W2898055118 cites W2043172254 @default.
• W2898055118 cites W2045584862 @default.
• W2898055118 cites W2047136624 @default.
• W2898055118 cites W2049863021 @default.
• W2898055118 cites W2052268330 @default.
• W2898055118 cites W2059600528 @default.
• W2898055118 cites W2062899296 @default.
• W2898055118 cites W2065432039 @default.
• W2898055118 cites W2066870043 @default.
• W2898055118 cites W2069444054 @default.
• W2898055118 cites W2075796682 @default.
• W2898055118 cites W2076939004 @default.
• W2898055118 cites W2089351680 @default.
• W2898055118 cites W2096505898 @default.
• W2898055118 cites W2097880588 @default.
• W2898055118 cites W2099194855 @default.
• W2898055118 cites W2102958109 @default.
• W2898055118 cites W2112697515 @default.
• W2898055118 cites W2119028999 @default.
• W2898055118 cites W2122524549 @default.
• W2898055118 cites W2124474450 @default.
• W2898055118 cites W2134811841 @default.
• W2898055118 cites W2140197284 @default.
• W2898055118 cites W2144611430 @default.
• W2898055118 cites W2146266794 @default.
• W2898055118 cites W2146348398 @default.
• W2898055118 cites W2150327446 @default.
• W2898055118 cites W2157387476 @default.
• W2898055118 cites W2287932189 @default.
• W2898055118 cites W2312944535 @default.
• W2898055118 cites W2562698917 @default.
• W2898055118 cites W2587479628 @default.
• W2898055118 cites W2616125272 @default.
• W2898055118 cites W2756389155 @default.
• W2898055118 doi "https://doi.org/10.1016/j.omtn.2018.10.004" @default.
• W2898055118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6234522" @default.
• W2898055118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30439648" @default.
• W2898055118 hasPublicationYear "2018" @default.
• W2898055118 type Work @default.
• W2898055118 sameAs 2898055118 @default.
• W2898055118 citedByCount "22" @default.
• W2898055118 countsByYear W28980551182019 @default.
• W2898055118 countsByYear W28980551182020 @default.
• W2898055118 countsByYear W28980551182021 @default.
• W2898055118 countsByYear W28980551182022 @default.
• W2898055118 countsByYear W28980551182023 @default.
• W2898055118 crossrefType "journal-article" @default.
• W2898055118 hasAuthorship W2898055118A5019939682 @default.
• W2898055118 hasAuthorship W2898055118A5045237664 @default.
• W2898055118 hasAuthorship W2898055118A5078187049 @default.
• W2898055118 hasAuthorship W2898055118A5080323628 @default.
• W2898055118 hasAuthorship W2898055118A5084705297 @default.
• W2898055118 hasBestOaLocation W28980551181 @default.
• W2898055118 hasConcept C104317684 @default.
• W2898055118 hasConcept C143065580 @default.
• W2898055118 hasConcept C153911025 @default.
• W2898055118 hasConcept C194583182 @default.
• W2898055118 hasConcept C2777300911 @default.
• W2898055118 hasConcept C2778776201 @default.
• W2898055118 hasConcept C2778943923 @default.
• W2898055118 hasConcept C36823959 @default.
• W2898055118 hasConcept C37113945 @default.
• W2898055118 hasConcept C501734568 @default.
• W2898055118 hasConcept C54355233 @default.
• W2898055118 hasConcept C86803240 @default.
• W2898055118 hasConceptScore W2898055118C104317684 @default.
• W2898055118 hasConceptScore W2898055118C143065580 @default.
• W2898055118 hasConceptScore W2898055118C153911025 @default.
• W2898055118 hasConceptScore W2898055118C194583182 @default.
• W2898055118 hasConceptScore W2898055118C2777300911 @default.

• next